Abstract

BackgroundChronic obstructive pulmonary disease is a progressive lung disease that is punctuated by periods of exacerbations (worsening of symptoms) that are attributable to viral infections. While rhinoviruses are most commonly isolated viruses during episodes of exacerbation, influenza viruses have the potential to become even more problematic with the increased likelihood of an epidemic.Methodology and Principal FindingsThis study examined the impact of current and potential pharmacological targets namely the systemic corticosteroid dexamethasone and the peroxisome proliferator-activated receptor- gamma agonist pioglitazone on the outcome of infection in smoke-exposed mice. C57BL/6 mice were exposed to room air or cigarette smoke for 4 days and subsequently inoculated with an H1N1 influenza A virus. Interventions were delivered daily during the course of infection. We show that smoke-exposed mice have an exacerbated inflammatory response following infection. While smoke exposure did not compromise viral clearance, precision cut lung slices from smoke-exposed mice showed greater expression of CC (MCP-1, -3), and CXC (KC, MIP-2, GCP-2) chemokines compared to controls when stimulated with a viral mimic or influenza A virus. While dexamethasone treatment partially attenuated the inflammatory response in the broncho-alveolar lavage of smoke-exposed, virally-infected animals, viral-induced neutrophilia was steroid insensitive. In contrast to controls, dexamethasone-treated smoke-exposed influenza-infected mice had a worsened health status. Pioglitazone treatment of virally-infected smoke-exposed mice proved more efficacious than the steroid intervention. Further mechanistic evaluation revealed that a deficiency in CCR2 did not improve the inflammatory outcome in smoke-exposed, virally-infected animals.Conclusions and SignificanceThis animal model of cigarette smoke and H1N1 influenza infection demonstrates that smoke-exposed animals are differentially primed to respond to viral insult. While providing a platform to test pharmacological interventions, this model demonstrates that treating viral exacerbations with alternative anti-inflammatory drugs, such as PPAR-gamma agonists should be further explored since they showed greater efficacy than systemic corticosteroids.

Highlights

  • Viral infections have been implicated as a major cause of chronic obstructive pulmonary disease (COPD) exacerbations

  • While providing a platform to test pharmacological interventions, this model demonstrates that treating viral exacerbations with alternative anti-inflammatory drugs, such as peroxisome proliferator-activated receptor (PPAR)-gamma agonists should be further explored since they showed greater efficacy than systemic corticosteroids

  • While we and others have shown that cigarette smoke exacerbates the inflammatory response to influenza virus infection [11,12,13], the whole body smoke-exposure system used in this study has not, to our knowledge, been shown to exacerbate the inflammatory response to influenza infection in mice

Read more

Summary

Introduction

Viral infections have been implicated as a major cause of chronic obstructive pulmonary disease (COPD) exacerbations. These episodes lead to declined lung function and concomitant acute deteriorations in respiratory health [1]. Hospitalization rates have been shown to increase during the influenza season, in unimmunized COPD populations [2]. These episodes place an exorbitant burden on health care systems and lead to high patient mortality. While rhinoviruses and respiratory syncytial virus are responsible for the largest fraction of those exacerbations, seasonal influenza has been shown to be a significant cause of acute episodes. While rhinoviruses are most commonly isolated viruses during episodes of exacerbation, influenza viruses have the potential to become even more problematic with the increased likelihood of an epidemic

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call